DJIA 18,080.14 21.45 0.12%
NASDAQ 5,092.09 36.02 0.71%
S&P 500 2,117.69 4.76 0.23%
market minute promo

Express Scripts (NASDAQ: ESRX)

87.34 0.45 (0.52%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

ESRX $87.34 0.52%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $86.97
Previous Close $86.89
Daily Range $86.13 - $87.58
52-Week Range $64.64 - $89.59
Market Cap $63.5B
P/E Ratio 32.91
Dividend (Yield) $0.00 (0.0%)
Volume 2,512,079
Average Daily Volume 3,479,729
Current FY EPS $5.43

Sector

Healthcare

Industry

Healthcare IT

Express Scripts (ESRX) Description

Provides pharmacy benefit management services, including retail drug card programs, mail pharmacy services, drug formulary management programs and other clinical management programs for HMOs, health insurers, third-party administrators and employers. Website: http://www.express-scripts.com/

News & Commentary

Rite Aid’s Incredible Turnaround: Beyond the Numbers

A look at Rite Aid’s strategic initiatives for catching up to -- and even passing -- its competitors.

5 Things UnitedHealth Wants You to Know

Does UnitedHealth's stock have more room to run? Here's what management had to say on trends that could make or break the nation's largest health insurer.

Notable ETF Outflow Detected - XLV, GILD, UNH, ESRX

Forget Gilead (GILD), Buy These Impressive Biotech Stocks Instead - Analyst Blog

3 Health Services Stocks Moving The Industry Upward

CVS Health Corporation (CVS) Ex-Dividend Date Scheduled for April 22, 2015

UnitedHealth's Earnings Deliver, but Risks Lurk Beneath the Surface

Shares of UnitedHealth are up 50% over the past year, but three major problems lurk beneath the surface, including a coming landmark Supreme Court decision.

Double-Digit Spike in Drug Costs Prescribes Profits for PBMs

A new report by employee benefit consultancy Aon Hewitt forecasts a 10% increase in employer drug costs through 2017, which puts a spotlight on pharmacy benefit management companies to assist employers, health plans, and government insurers such as Medicare and Medicaid to control prescription spending.

What Could Possibly Go Wrong With Gilead Sciences Inc. Stock?

Three risks for Gilead Sciences.

AbbVie's HCV Treatment Granted Priority Review in Japan - Analyst Blog

See More ESRX News...

ESRX's Top Competitors

ESRX $87.34 (0.52%)
Current stock: ESRX
UNH $118.69 (0.36%)
Current stock: UNH
ANTM $154.28 (0.05%)
Current stock: ANTM
FMS $43.18 (1.41%)
Current stock: FMS